JOURNAL ARTICLE
Add like
Add dislike
Add to saved papers

Primary parotid malignancies. A clinical and pathologic review.

One hundred ninety-four patients with primary malignant tumors of the parotid gland who underwent surgery at the Mayo Clinic (1970 through 1987) are reviewed. Survival patterns were analyzed using the Kaplan-Meier product-limit method that separated histologic results into three significantly different groups. Survival rate was highest for patients with acinic cell, adenoid cystic, and low-grade mucoepidermoid carcinomas; intermediate for patients with high-grade mucoepidermoid carcinomas; and lowest for the remaining six histologic types encountered. Cox multiple linear regression was used to identify patient and tumor characteristics with greatest prognostic significance. In order of decreasing strength, regional metastatic involvement, pain, male gender, grade, stage, and advancing age all demonstrated independent prognostic significance. Fifty-three percent of patients requiring facial nerve sacrifice were asymptomatic at presentation. A high positive correlation was observed between advancing grade and stage.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app